Characteristics of Eyes With Neovascular Age-Related Macular Degeneration Requiring Frequent Anti-vascular Endothelial Growth Factor Injections
- PMID: 38249251
- PMCID: PMC10797311
- DOI: 10.7759/cureus.50817
Characteristics of Eyes With Neovascular Age-Related Macular Degeneration Requiring Frequent Anti-vascular Endothelial Growth Factor Injections
Abstract
Objective In this study, we aimed to determine the characteristics of neovascular age-related macular degeneration (AMD) patients requiring frequent anti-vascular endothelial growth factor (VEGF) therapy. Methods This was a retrospective observational study involving the review of 32 eyes of 31 patients (25 men and six women, mean age: 74.3 years) treated with anti-VEGF injections for less than eight weeks and at least one year of follow-up. The subtype of macular neovascularization (MNV), follow-up duration, number of injections, visual acuity, and exudative changes during the study period were evaluated. Results Twenty-nine eyes (90.6%) had MNV under the retinal pigment epithelium (RPE), including 11 eyes with type 1 MNV and 18 eyes with polypoidal choroidal vasculopathy (PCV). Only three eyes had type 2 MNV (9.4%) above the RPE. The mean follow-up period was 28.7 ± 16.5 months, and the mean number of injections was 21.5 ± 11.8. The mean visual acuity [logarithm of the minimum angle of resolution (logMAR) units] was 0.19 ± 0.23 at the initial visit to our hospital, which decreased non-significantly to 0.24 ± 0.4 at the final visit (p=0.63). The exudation in four eyes (two with type 1 MNV and two with PCV) never resolved. The exudation remained in 27 eyes (84%) even after every four weeks of treatment, and it was present in five eyes (16%) in the treatment interval of eight weeks. Conclusions In the eyes receiving frequent anti-VEGF injections, the sub-RPE MNV might have affected the response to the treatment. Although patients requiring frequent anti-VEGF therapy did not have a significant decrease in their visual acuity, 84% of the eyes had exudations even with monthly injections.
Keywords: dry macula; neovascular age-related macular degeneration; non-responders; polypoidal choroidal vasculopathy; tachyphylaxis.
Copyright © 2023, Taketani et al.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures

Similar articles
-
Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.Eur J Ophthalmol. 2021 May;31(3):1267-1280. doi: 10.1177/1120672120913012. Epub 2020 Mar 31. Eur J Ophthalmol. 2021. PMID: 32228025
-
Morphological changes of macular neovascularization during long-term anti-VEGF-therapy in neovascular age-related macular degeneration.PLoS One. 2023 Dec 22;18(12):e0288861. doi: 10.1371/journal.pone.0288861. eCollection 2023. PLoS One. 2023. PMID: 38134207 Free PMC article.
-
Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.BMC Ophthalmol. 2016 Jul 27;16:127. doi: 10.1186/s12886-016-0305-2. BMC Ophthalmol. 2016. PMID: 27465105 Free PMC article. Clinical Trial.
-
Radiotherapy for neovascular age-related macular degeneration.Cochrane Database Syst Rev. 2020 Aug 26;8(8):CD004004. doi: 10.1002/14651858.CD004004.pub4. Cochrane Database Syst Rev. 2020. PMID: 32844399 Free PMC article.
-
[Polypoidal choroidal vasculopathy].Nippon Ganka Gakkai Zasshi. 2012 Mar;116(3):200-31; discussion 232. doi: 10.4264/numa.71.282. Nippon Ganka Gakkai Zasshi. 2012. PMID: 22568102 Review. Japanese.
References
-
- Ranibizumab for neovascular age-related macular degeneration. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. N Engl J Med. 2006;355:1419–1431. - PubMed
-
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, et al. N Engl J Med. 2006;355:1432–1444. - PubMed
-
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Heier JS, Brown DM, Chong V, et al. Ophthalmology. 2012;119:2537–2548. - PubMed
-
- An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE, Lalwani GA, Rosenfeld PJ, et al. Am J Ophthalmol. 2007;143:566–583. - PubMed
LinkOut - more resources
Full Text Sources